@FierceMedDev: Twisted fibers make low-cost artificial muscle to be used in robotics, prosthetics. Item | Follow @FierceMedDev
@MarkHFierce: VC options may have declined in the device and Dx worlds, but they're far from gone. See: Abingworth. Story | Follow @MarkHFierce
@MichaelGFierce: A tattoo to deliver a treatment for deadly sandfly-borne skin disease? It's a first. Item from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Only 15 percent of all ovarian cancers are detected in early stages--but nVision Medical plans to change all that. Article | Follow @EmilyWFierce
> AdvaMed and other medical device industry reps want India's parliament to make sure it ensures "sufficient dialogue" with stakeholders before it revises a proposed bill that would modernize how the sector is regulated in the country. Story
> A bill sponsored by Utah Republican Sen. Orrin Hatch that would repeal the medical device tax advanced to the Senate Finance Committee. Story
> Cardica ($CRDC) said it won the FDA's 510(k) clearance for a new surgical tool and related part designed for stapling of tissue during intestinal and other procedures. Item
> A federal judge dismissed a lawsuit alleging that a Stryker ($SYK) surgical tool caused the misalignment of her knee implant. Story (sub. req.)
> Newly-public medical device manufacturer LDR Holding ($LDRH) lost nearly $15 million in its fourth quarter and $27.8 million for all of 2013, both jumps over the previous year. Story
Biotech News
@FierceBiotech: Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck. More | Follow @FierceBiotech
@JohnCFierce: Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months. News | Follow @JohnCFierce
@DamianFierce: Bayer looks to boost its R&D budget to $15.5B over the next three years. News | Follow @DamianFierce
@EmilyMFierce: Brain cell communication plays role in regulating tau in Alzheimer's. Story | Follow @EmilyMFierce
> Celgene gambles $50M on Abide and its R&D work on enzyme 'superfamily'. More
> Bayer plans to ratchet up its R&D spend and chase down some deals. Article
Pharma News
@FiercePharma: Best-read FP story yesterday: Eliquis earns best safety score in its class in analysis of FDA adverse event reports. Piece | Follow @FiercePharma
@TracyStaton: J&J's high-stakes argument against a $1.2B Risperdal fine begins in Arkansas' top court. News | Follow @TracyStaton
@EricPFierce: Mylan earnings get shot in the arm from epinephrine shortage. More | Follow @EricPFierce
@CarlyHFierce: Bayer's 2013 earnings are out. Release: More. BloombergNews' take: Article | Follow @CarlyHFierce
> GSK trims Witty's bonus in face of China probe. Story
> Endo loss widens, R&D chief departs amid regulatory struggles. Article